About
Iovance Biotherapeutics develops tumor-infiltrating lymphocyte (TIL) therapies that harness and enhance a patient's immune cells to recognize and attack diverse cancer cells in solid tumors.
Explore Iovance Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.